Copyright © Inderes 2011 - present. All rights reserved.

CombiGene

2,54

 

SEK

 

+3,67 %

Mindre end 1K følgere

COMBI

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+3,67%
+5,83%
-0,78%
+6,72%
-9,29%
-22,32%
-66,36%
-76,67%
-97,35%

CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.

Læs mere
Markedsværdi
50,3 mio. SEK
Aktieomsætning
611,75 t SEK
Omsætning
330 t
EBIT %
-14.309,09 %
P/E
-
Udbytteafkast, %
-
Finanskalender
12.6
2025

Generalforsamling '25

22.8
2025

Delårsrapport Q2'25

13.2
2026

Årsrapport '25

ViserAlle indholdstyper
Eksterne analyser

CombiGene: Making place for new ventures - VH Corp

• All research activities discontinued • Notice of an extraordinary general meeting on February 20, 2025 • Q&A with chairman Luca Di Stefano After a strategic evaluation of its operations, CombiGene’s board decided to discontinue all research activities...

CombiGene

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Eksterne analyser

CombiGene: Strategic consequences after CG01 - VH Corp

* Implementing cost savings and new priorities * New propositions from the main shareholder * Our revised fair value estimate is SEK 8.27 (12.19) per share In our previous analysis, CombiGene was focused on outlicensing the epilepsy project CG01 again...

CombiGene
Eksterne analyser

CombiGene: New priorities after strategic decision - VH Corp

* Terminating the CG01 programme * Implementing cost savings to prolong the financial runway * Our fair value estimate is under review Recently, CombiGene announced new priorities in its pipeline and a cost saving programme to prolong its financial runway...

CombiGene
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.